Takeda shares drop after report on $6 billion jury award over Actos
TOKYO (Reuters) - Shares in Takeda Pharmaceutical Co Ltd (4502.T) were down nearly 6 percent on Tuesday morning after Bloomberg news reported that a U.S. jury ordered it to pay $6 billion in punitive damages in a case claiming it hid cancer risks of its Actos diabetes drug.
Takeda representatives could not immediately be reached for comment.
Takeda's shares were down 5.7 percent at midday at 4,545 yen, after falling as far as 4,483, a six-month low.
(Reporting by Ritsuko Shimizu and Edmund Klamann; Editing by Dominic Lau)
- China food scandal spreads, drags in Starbucks, Burger King and McNuggets in Japan |
- U.S. court rulings create new uncertainty over Obamacare
- Israel pounds Gaza despite international peace efforts |
- EU readies possible capital, tech sanctions on Russia
- Islamic State crushes and coerces on march towards Baghdad